TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25923229
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (sequential therapy and modified bismuth-included quadruple therapy)
Study: 17310303
Drug: Parecoxib (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parecoxib (40 mg, administered twice within 12 h)
Study: 17310303
Drug: Propacetamol (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propacetamol (2 g, administered twice within 12 h)
Study: 15362796
Drug: Proton pump
Normalized name: Proton pump inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proton pump inhibitor (group III)
Study: 15362796
Drug: H2-receptor antagonist
Normalized name: H2-receptor antagonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: H2-receptor antagonist (group II)
Study: 1530028
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (group I)
Study: 16060412
Drug: Nifedipine GITS
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine GITS 20 mg
Study: 2697728
Drug: Benazepril 20
Normalized name: benazepril 20 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benazepril 20 mg o.d.
Study: 2697728
Drug: Benazepril 10
Normalized name: benazepril 10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benazepril 10 mg b.i.d.
Study: 1505563
Drug: Benazepril 20
Normalized name: benazepril 20 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benazepril 20 mg b.i.d.
Study: 29953782
Drug: Cytoreductive surgery
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cytoreductive surgery and six to eight courses of intravenous chemotherapy
Study: 26346592
Drug: Vortioxetine 5
Normalized name: vortioxetine 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vortioxetine 5 mg (elderly patients)
Study: 30157357
Drug: L-carnitine combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-carnitine combined with coenzyme Q10
Study: 26864193
Drug: IP ketorolac
Approvals — FDA: no, EMA: no, PMDA: no
Description: IP ketorolac 30 mg + intravenous saline
Study: 7549168
Drug: Intravenous ketorolac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ketorolac 30 mg
Study: 26864193
Drug: Intraperitoneal saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraperitoneal saline + intravenous saline
Study: 24827696
Drug: Periarticular injection
Normalized name: camphor
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Periarticular injection analgesia (PAI) - mixture of ropivacaine, saline, epinephrine, morphine hydrochloride, and dexamethasone
Study: 16135141
Drug: UVB311 nm
Normalized name: NM-004
DrugBank: NM-004 (DB18066)
Approvals — FDA: no, EMA: no, PMDA: no
Description: UVB311 nm therapy
Study: 16135141
Drug: Broad-band UVB
Normalized name: Band-Aid Hurt-Free
Approvals — FDA: no, EMA: no, PMDA: no
Description: Broad-band UVB therapy
Study: 7828294
Drug: Nadolol (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nadolol (40 mg/d)
Study: 7828294
Drug: Atenolol (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol (25 mg/d)
Study: 7828294
Drug: Nadolol (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nadolol (20 mg/d)
Study: 2200382
Drug: Atenolol (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol (50 mg/d)
Study: 30106956
Drug: Discontinuation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinuation of mass azithromycin distribution
Study: 30106956
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of continuation vs discontinuation
Study: 21637969
Drug: Azelnidipine (8-16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azelnidipine (8-16 mg/day)
Study: 21637969
Drug: Amlodipine (2.5-5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine (2.5-5 mg/day)
Study: 19675101
Drug: Flaxseed oil
Normalized name: Flaxseed Oil
DrugBank: Linseed oil (DB11357)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flaxseed oil (62% ALA, 5.4 g/d)
Study: 15382590
Drug: Manipulative therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manipulative therapy (French method of R. Meigne)
Study: 8100628
Drug: Syrup of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Syrup of ipecac 30 ml followed by activated charcoal 50 g in sorbitol
Study: 30892108
Drug: Cholestyramine 15%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholestyramine 15% Ointment applied twice a day for 2 months
Study: 30892108
Drug: Placebo Ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Ointment applied twice a day for 2 months
Study: 22700888
Drug: Carvedilol (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carvedilol (50 mg twice daily)
Study: 17013444
Drug: Peg‐IFNalpha‐2b 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peg‐IFNalpha‐2b 1.5 mcg/kg QW x 48 weeks plus 800‐1200 mg ribavirin (Arm B)
Study: 9272343
Drug: Various pertussis
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various pertussis vaccines
Study: 29253089
Drug: Standard-Dose Influenza
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-Dose Influenza Vaccine (Fluviral, GSK)
Study: 29253089
Drug: High-Dose Influenza
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-Dose Influenza Vaccine (FluzoneHD, Sanofi)
Study: 18770962
Drug: Suspension of
Normalized name: Suspension of heat killed (autoclaved) Mycobacterium w
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suspension of the vaginal apex to the uterosacral ligaments or sacrospinous ligaments
Study: 15880023
Drug: Everolimus 0.75-1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Everolimus 0.75-1.5 mg bid plus reduced-exposure cyclosporine (CsA) and prednisone
Study: 10469713
Drug: 100 mg/day
Normalized name: infigratinib phosphate 100 mg/day (100 mg x 1) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg/day danazol for 6 months
Study: 1654756
Drug: 16-gauge intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: 16-gauge intravenous catheter
Study: 1654756
Drug: 20-gauge intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20-gauge intravenous catheter
Study: 8471832
Drug: Pindolol 5
Normalized name: pindolol 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pindolol 5 mg
Study: 29316176
Drug: Prandial insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prandial insulin glulisine injection timing adjustment based on continuous glucose monitoring (arm B)
Study: 29316176
Drug: Pre-breakfast insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pre-breakfast insulin glulisine injection (arm A)
Study: 29316176
Drug: Prandial insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prandial insulin glulisine dosage (arm B)
Study: 29316176
Drug: Prandial insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prandial insulin glulisine dosage (arm A)
Study: 25296241
Drug: Intrapleural tPA/DNase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrapleural tPA/DNase therapy
Study: 10346769
Drug: Promethazine (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Promethazine (25 mg for adults and 0.5/kg for children)
Study: 28137739
Drug: Etoposide 50
Normalized name: etoposide 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etoposide 50 mg/m2 on days 1-5 and cisplatin 50 mg/m2 on days 1 and 8 every 4 weeks for two cycles (EP arm)
Study: 28137739
Drug: Paclitaxel 45
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel 45 mg/m2 and carboplatin (AUC 2) on day 1 weekly (PC arm)
Study: 30517889
Drug: Active CPAP
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active CPAP treatment
Study: 17406837
Drug: Arginine (Arg;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arginine (Arg; 20 g)
Study: 18035195
Drug: Ibutilide 0.005
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibutilide 0.005 mg/kg
Study: 8752805
Drug: Ibutilide 0.025
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibutilide 0.025 mg/kg
Study: 6419419
Drug: Valproic acid
Normalized name: Valproic Acid
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Valproic acid (Depakene capsules, Abbott)
Study: 25246664
Drug: Inhaled mannitol
Normalized name: mannitol Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled mannitol 400 mg twice a day for 52 weeks
Study: 21796421
Drug: 17 alpha-hydroxyprogesterone
Normalized name: 17 alpha-hydroxyprogesterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 17 alpha-hydroxyprogesterone caproate (17‐OHPC) 250 mg intramuscularly
Study: 9414326
Drug: Daily contact
Normalized name: CONTACT LENS DAILY CLEANER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily contact with a nurse and home monitoring of uterine activity
Study: 26320081
Drug: Integrated intensive
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Integrated intensive smoking plus alcohol intervention using cognitive behavioral therapy (CBT)
Study: 22818224
Drug: Intravenous omeprazole
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous omeprazole 0.5mg/kg every 12 hours
Study: 16540816
Drug: Family-focused cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Family-focused cognitive behavioral therapy (CBT; the Building Confidence Program)
Study: 16540816
Drug: Child-focused cognitive
Normalized name: Senna-Relief Childs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Child-focused cognitive behavioral therapy (CBT) with minimal family involvement
Study: 15978303
Drug: Azelastine nasal
Normalized name: azelastine nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azelastine nasal spray (2 sprays per nostril twice daily)
Study: 9311405
Drug: Intravenous morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous morphine (50 mg)
Study: 9311405
Drug: Intraperitoneal morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraperitoneal morphine (50 mg)
Study: 30340425
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g of leucine immediately after a mixed meal (MEAL-LEU)
Study: 30340425
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g of leucine 180 min after a mixed meal (MEAL-LEU180)
Study: 27541690
Drug: Dietary LCω3PUFA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary LCω3PUFA intake of at least 500 mg/d
Study: 27541690
Drug: Not meeting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Not meeting the LCω3PUFA recommendation (<500 mg/d)
Study: 17568402
Drug: Buprenorphine with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine with ultra-low-dose naloxone
Study: 12027854
Drug: Thoracic epidural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thoracic epidural analgesia with a bupivacaine/morphine infusion (EPI-group, n=6)
Study: 12027854
Drug: Continuous i.v.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous i.v. infusion of morphine (MO-group, n=8)
Study: 24519200
Drug: Oxybutynin 10
Normalized name: oxyBUTYnin 10% transdermal gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxybutynin 10 mg daily
Study: 20947066
Drug: METH (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: METH (20 mg)
Study: 9925239
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of ASA and DP
Study: 554446
Drug: Haloperidol (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol (10 to 60 mg daily)
Study: 25618965
Drug: Control (routine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (routine therapy alone)
Study: 23072088
Drug: Non-acupoints treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-acupoints treatment
Study: 12515574
Drug: Basiliximab (20mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basiliximab (20mg intravenous bolus on day 0 and day 4)
Study: 10713317
Drug: Warfarin dosage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin dosage scheme based on a transition factor of 2.3 times the phenprocoumon dose; no specific dosage or duration mentioned.
Study: 1567347
Drug: Multicomponent psychological
Normalized name: meningococcus B, multicomponent vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multicomponent psychological treatment (relaxation, thermal biofeedback, and cognitive therapy)
Study: 2416566
Drug: Pirmenol, 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pirmenol, 200 mg twice daily
Study: 29633507
Drug: GV1001 0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: GV1001 0.4 mg, 2‐week interval
Study: 29633507
Drug: GV1001 0.56
Approvals — FDA: no, EMA: no, PMDA: no
Description: GV1001 0.56 mg, 2‐week interval
Study: 29633507
Drug: GV1001 0.56
Approvals — FDA: no, EMA: no, PMDA: no
Description: GV1001 0.56 mg, 4‐week interval
Study: 10228867
Drug: 5‐FU plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5‐FU plus continuous infusion of low‐dose CDDP (A‐2, B‐2)
Study: 10228867
Drug: 5‐FU plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5‐FU plus bolus infusion of CDDP (A‐1, B‐1)
Study: 1887821
Drug: 0.625 mg
Normalized name: estrone 0.625 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.625 mg conjugated estrogen daily plus variable-resistance weight training
Study: 1887821
Drug: 0.625 mg
Normalized name: estrone 0.625 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.625 mg conjugated estrogen daily
Study: 31601239
Drug: HemoSphere with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: HemoSphere with HPI used to guide treatment
Study: 22489072
Drug: 7-item predictive
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 7-item predictive score including age <1 year, epilepsy, congenital/genetic conditions, history of transplant, enteral tube, hemoglobin <10 g/dL, blood culture drawn in the preceding 72 hours
Study: 15567879
Drug: GnRH antagonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH antagonist + rFSH
Study: 8901789
Drug: 300 g
Normalized name: Zantac 300 GELdose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 g Brussels sprouts/d for 3 weeks
Study: 8901789
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg eugenol/d in capsule form
Study: 1876744
Drug: Mepivacaine 1%
Normalized name: mepivacaine 1% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mepivacaine 1% 40 ml + phentanyl 100 micrograms
Study: 1876744
Drug: Mepivacaine 1%
Normalized name: mepivacaine 1% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mepivacaine 1% 40 ml + subcutaneous phentanyl 100 micrograms
Study: 1876744
Drug: Mepivacaine 1%
Normalized name: mepivacaine 1% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mepivacaine 1% 40 ml (control group)
Study: 6283645
Drug: tiapride (900
Approvals — FDA: no, EMA: no, PMDA: no
Description: tiapride (900 mg per day for three months)
Study: 30081380
Drug: 0.2 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg/kg ketamine infusion
Study: 27143213
Drug: Dabigatran 220
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dabigatran 220 mg once daily (starting with 110 mg half-dose, 1-4 hours after surgery)
Study: 27143213
Drug: Enoxaparin 40
Normalized name: ENOXAPARIN 40MG/0.4ML INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin 40 mg once daily (starting the evening before surgery)
Study: 26121789
Drug: Hypotonic electrolyte
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypotonic electrolyte solution with 2.6% glucose (HT)
Study: 12925471
Drug: Etomidate 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etomidate 0.2 mg kg(‐1)
Study: 12925471
Drug: Etomidate 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etomidate 0.3 mg kg(‐1)
Study: 12925471
Drug: Etomidate 0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etomidate 0.4 mg kg(‐1)
Study: 10683103
Drug: Creatine (Cr)
DrugBank: Creatine (DB00148)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Creatine (Cr) supplementation (5 g of Cr plus 1 g of sucrose 4x per day)
Study: 10683103
Drug: Placebo (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (6 g of sucrose placebo 4x per day)
Study: 30357297
Drug: Myo-inositol (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Myo-inositol (40 mg/kg every 12 hours for up to 10 weeks)
Study: 10512080
Drug: Amisulpride 50
Normalized name: amisulpride 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amisulpride 50 mg/day
Study: 10200742
Drug: Amisulpride 100
Normalized name: amisulpride 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amisulpride 100 mg/day
Study: 8848950
Drug: Clomipramine (100-150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clomipramine (100-150 mg/day)
Study: 8848950
Drug: Moclobemide (400-600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moclobemide (400-600 mg/day)
Study: 2330930
Drug: Oral rhesus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral rhesus rotavirus vaccine at a dose of 10(4) plaque‐forming units
Study: 25652873
Drug: AS03-adjuvanted H5N1
Normalized name: AS03 Adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: AS03-adjuvanted H5N1 influenza vaccine (1·9 μg or 3·75 μg hemagglutinin antigen)
Study: 15572199
Drug: Tobramycine eye
Normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tobramycine eye drops alone or in combination with cyclosporine A, diclofenac, or rimexolone
Study: 2198822
Drug: Intravenous immunoglobulin-G
Normalized name: immunoglobulin G
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulin-G (IVIG)
Study: 26048185
Drug: Dapagliflozin/metformin XR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapagliflozin/metformin XR FDC tablets (administered with a light-fat meal)
Study: 23354187
Drug: Routine heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine heparin R‐AHD
Study: 23354187
Drug: Half-dose heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Half-dose heparin R‐AHD
Study: 23354187
Drug: Routine heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine heparin DNHD (control)
Study: 23354187
Drug: Routine heparin-mixed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine heparin-mixed AHD PR
Study: 8932015
Drug: Air-fluidised bed
Normalized name: air
DrugBank: Medical air (DB09337)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Air-fluidised bed therapy at 32 degrees C (Group B)
Study: 1873204
Drug: Bath treatment
Normalized name: Aveeno Soothing Bath Treatment
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bath treatment (8-methoxypsoralen)
Study: 6355795
Drug: Combination chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination chemotherapy (Tinidazole and Cephamandole)
Study: 30326639
Drug: Reduced dairy
Normalized name: Beano Dairy Defense
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reduced dairy intake (−14.6 ± 3.0 g/day)
Study: 30326639
Drug: Maintained dairy
Normalized name: Beano Dairy Defense
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintained dairy intake (−4.0 ± 2.0 g/day)
Study: 30326639
Drug: Increased dairy
Normalized name: Beano Dairy Defense
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increased dairy intake (+13.8 ± 4.1 g/day)
Study: 26764321
Drug: 20 g
Normalized name: PEG-20 glyceryl oleate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 g LNS (Lipid-Based Nutrient Supplement)
Study: 26764321
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg iron + 400 μg folic acid (IFA)
Study: 22555894
Drug: Oral methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral methylprednisolone 1 mg/kg/d (tapered gradually)
Study: 22555894
Drug: Intrapolyp injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrapolyp injection of triamcinolone acetonide (0.3 mL, 40 mg/mL)
Study: 22555894
Drug: Topical triamcinolone
Normalized name: triamcinolone Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical triamcinolone acetonide (55 µg, 2 times daily for 1 month)
Study: 22555894
Drug: Intrapolyp injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrapolyp injection vs Topical triamcinolone
Study: 20473745
Drug: Shenmai Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shenmai Injection (SMI) given to the observation group for 14 days along with basic treatment including polarized liquid therapy.
Study: 20473745
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group received basic treatment including polarized liquid therapy without SMI.
Study: 15476904
Drug: Telmisartan 40
Normalized name: telmisartan 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telmisartan 40 mg once daily for 12 months
Study: 18712038
Drug: Amlodipine 5
Normalized name: amlodipine 5 MG
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amlodipine 5 mg once daily for 12 months
Study: 12874080
Drug: Short-course clindamycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short-course clindamycin (3 doses)
Study: 12874080
Drug: Long-course clindamycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-course clindamycin (15 doses)
Study: 1524898
Drug: Breast-conserving therapy
Normalized name: chicken breast preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Breast-conserving therapy (BCT)
Study: 8945129
Drug: Daily vaginal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily vaginal douche for one day (Group A)
Study: 8945129
Drug: Daily vaginal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily vaginal douche for four days (Group B)
Study: 28315479
Drug: personalized pharmaceutical
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: personalized pharmaceutical and general education
Study: 19728887
Drug: 500 mcg
Normalized name: Nplate 500 MCG Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mcg darbepoetin alfa every three weeks (Q3W)
Study: 19728887
Drug: 2.25 mcg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.25 mcg/kg darbepoetin alfa weekly (QW)
Study: 15966757
Drug: Cocaine 20
Normalized name: cocaine 20 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocaine 20 mg
Study: 15966757
Drug: Cocaine 40
Normalized name: cocaine 40 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocaine 40 mg
Study: 22122605
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group without treatment
Study: 24946226
Drug: Topical sucralfate
Normalized name: Sucralfate
DrugBank: Sucralfate (DB00364)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical sucralfate mouthwash